Evidence map›Paper›PMID 39530508›Full record

ArticleJournal of medicinal chemistry2024

Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia.

Xuejiao Shirley Guo, Sandeep Atla, Satyanarayana Nyalata, Yugendar R Alugubelli, Peng-Hsun Chase Chen, Shiqing Xu, Wenshe Ray Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Discovery of a Highly Potent and Selective ENL Degrader.Journal of medicinal chemistry · 2026
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuejiao Shirley GuoTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Sandeep AtlaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Satyanarayana NyalataTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Yugendar R AlugubelliTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Peng-Hsun Chase ChenTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0001-9822-6398
Shiqing XuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0001-6260-9290
Wenshe Ray LiuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0002-7078-6534

Funding

Use of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026
$2.6M
A Multiplatform Approach to Develop ENL-Targeting Molecules as Drug Candidates for Acute Myeloid LeukemiaR01CA291968 · NCI · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2024 to 2026
$2.4M
Targeting the ENL YEATS domain for the development of anti-leukemia agentsR21CA267512 · NCI · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2022 to 2023
$377k
NCI NIH HHS R01 CA291968NCI NIH HHS R21 CA267512NIGMS NIH HHS R35 GM145351
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is the second most prevalent and fatal form of leukemia. The growth of AML cells harboring oncogenic MLL rearrangements relies on the YEATS domain-containing protein ENL. Many small molecule inhibitors targeting ENL have been developed. To prioritize these inhibitors for in vivo studies, a NanoBRET system was introduced to evaluate their cellular permeability and potency. This screening identified inhibitor

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteAdministration, OralAnimalsCell Line, TumorCell ProliferationHumansMiceStructure-Activity RelationshipXenograft Model Antitumor AssaysAntineoplastic Agents

Identifiers

PMID39530508
PMCPMC11613437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.